Accepted Manuscript

One-year risks of stroke and death in patients with atrial fibrillation from different clinical settings: The Gulf SAFE registry and Darlington AF registry

Yan-Guang Li, Kazuo Miyazawa, Andreas Wolff, Mohammad Zubaid, Alawi A. Alsheikh-Ali, Kadhim Sulaiman, Gregory Y.H. Lip

PII: S0167-5273(18)34355-9
DOI: doi:10.1016/j.ijcard.2018.08.091
Reference: IJCA 26907
To appear in: International Journal of Cardiology

Received date: 6 July 2018
Revised date: 15 August 2018
Accepted date: 29 August 2018


This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.
One-year risks of stroke and death in patients with atrial fibrillation from different clinical settings: The Gulf SAFE Registry and Darlington AF Registry

Yan-Guang Li, PhD (1,2), Kazuo Miyazawa, MD (1), Andreas Wolff, MD (3), Mohammad Zubaid, MD (4), Alawi A. Alsheikh-Ali, MD (5), Kadhim Sulaiman, MD (6), Gregory Y.H. Lip, MD (1,7)

(1) Institute of Cardiovascular Sciences, University of Birmingham, Birmingham, United Kingdom; (2) Department of Cardiology, Chinese PLA Medical School, Beijing, China; (3) Division of Family Practice, Chilliwack General Hospital, Chilliwack, British Columbia, Canada; (4) Department of Medicine, Faculty of Medicine, Kuwait University, Kuwait, Kuwait; (5) College of Medicine, Mohammed Bin Rashid University of Medicine and Health Sciences, Dubai, United Arab Emirates; (6) National Heart Center, Royal Hospital, Muscat, Oman; (7) Aalborg Thrombosis Research Unit, Department of Clinical Medicine, Aalborg University, Aalborg, Denmark.

Corresponding Author
Professor Gregory Y.H. Lip
Institute of Cardiovascular Sciences,
University of Birmingham, Birmingham, England, United Kingdom
Tel: +44 121 5075080; Fax: +44 121 507 5503; Email: g.y.h.lip@bham.ac.uk
Declarations of interest
None directly related to this paper. GYHL: Consultant for Bayer/Janssen, BMS/Pfizer, Medtronic, Boehringer Ingelheim, Novartis, Verseon and Daiichi-Sankyo. Speaker for Bayer, BMS/Pfizer, Medtronic, Boehringer Ingelheim, and Daiichi-Sankyo. No fees are directly received personally.
Other authors: None declared.

Keywords: Atrial fibrillation, Stroke prevention, Anticoagulation, Stroke and Mortality, Clinical setting
ABSTRACT

Background: AF patients from different clinical settings may have varying outcomes. We aimed to provide patient-level comparisons using two cohorts of patients with AF from different settings.

Methods: The clinical characteristics, prescription of OAC, one-year risks of stroke and mortality were compared between patients with AF included into the Darlington AF registry (general practice-based cohort from the United Kingdom, n=2258) and the Gulf SAFE (Survey of atrial fibrillation events) registry (emergency room-based cohort from the Gulf countries, n=1740).

Results: Patients from the Gulf SAFE registry were younger, had high prevalence of diabetes, vascular disease, heart failure. Patients from the Darlington registry had higher prevalence of hypertension, previous thromboembolism event, and higher mean stroke risk. OAC use was <60% in high stroke risk patients in both registries. On multivariate analyses, patients from Gulf SAFE were independently associated with higher risks of stroke (odds ratio, 2.18 [1.47-3.23]) and mortality (odds ratio, 1.67 [1.31-2.14]), especially in those with high CHA2DS2-VASc score (≥2 in males, ≥3 in females) (Darlington vs. Gulf SAFE: 3.51% vs. 5.63 for stroke; 11.4% vs. 16.8% for mortality)

Conclusions: Differences regarding AF patients profile, OAC use and outcomes exist in varying clinical settings as reflected by registries from different origins. Tailored AF management strategy are needed to fit in different clinical settings.
**Introduction**

Atrial fibrillation (AF) is the most prevalent arrhythmia worldwide, conferring an increased risk of ischemic stroke, systemic embolism (SE), heart failure (HF) and mortality\(^1,2\). During the past decades, the prevalence of AF has increased significantly because of increasingly prevalent contributing factors, including an ageing population, hypertension, diabetes mellitus (DM), coronary artery disease (CAD) and HF\(^3\). Nevertheless, more limited data on AF epidemiology are available from the Middle East (ME), when compared to Western countries and Asia\(^4-6\).

Management of AF requires a holistic and integrated procedure, to Avoid stroke, achieve Better symptom management and reduce Cardiovascular and comorbidity (the ABC pathway)\(^7\). AF-related ischemic stroke is one of the most devastating outcomes for AF, which can be reduced by oral anticoagulation (OAC)\(^8,9\).

Nevertheless, the prescription rates of OAC and the quality of anticoagulation control varies between different geographical areas\(^10\), which may have implications for outcomes among AF patients\(^11-13\). There is also the perception that outcomes differ by region, ethnicity and healthcare provider, even amongst patients with AF. Hence, evaluating AF epidemiology and outcomes between different populations may help us understand the global scenario of this common arrhythmia. For example, differences in OAC prescription rates and related outcomes among AF patients from the United Kingdom (UK) and the Middle East (ME) have never been previously reported.
In this study, we aimed to provide patient level comparisons of clinical characteristics, OAC use, and one-year risks of stroke and mortality amongst two diverse cohorts of patients with AF.

Materials and Methods

Individual data from two registries were used in this study, including the Darlington AF Registry from UK and the Gulf SAFE (Gulf Survey of Atrial Fibrillation Events) Registry from ME. Details of both registries have been published\textsuperscript{14,15}.

In brief, the study population of the Darlington Registry was derived from 11 general practices serving the town of Darlington, County Durham, UK. All patients with known vital status in March 2013 were eligible for inclusion. Majority of the AF patients in the Darlington Registry were Caucasian (over 96\%\textsuperscript{16}). Data collection of this study was performed with GRASP-AF (Guidance on Risk Assessment and Stroke Prevention in Atrial Fibrillation) audit tool, which can interrogate primary care database with a pre-defined set of search criteria. Information regarding demographic profile, AF diagnosis, comorbidities, treatment, and outcomes were collected. All events during 12 months of follow-up were manually reviewed and confirmed by imaging and/or stroke physician opinion. Details about antithrombotic therapy (ATT), OAC were identified through database audit. Patients were classified as using anticoagulants or antiplatelet agents if a prescription was issued within the last 6 months of the data collection.

The Gulf SAFE study was a prospective, multinational, observational registry of patients visiting the emergency room with AF with a 12-month of follow-up. Detailed methodology was previously described\textsuperscript{15}. Patients were recruited between October 2009 and June 2010.
from emergency room of 23 hospitals in six Gulf countries from ME, including Bahrain, Kuwait, Qatar, Oman, Yemen, and United Arab Emirates. Data was collected by standardized case report form and entered online. Aspects regarding the data included patient demographics, medical history, and outcomes. ATT and OAC prescription were also identified at discharge which was also the start of follow-up. For patients on Vitamin K antagonists who had at least three INR checks, the time in therapeutic range (TiTR) was calculated using the well accepted Rosendaal method17.

After the exclusion of patients who died within 30 days after recruitment (n=137) and severe mitral stenosis (n=167), a total of 3998 patients with AF entered the final analysis, with 2258 from the Darlington and 1740 from the Gulf SAFE Registry (Supplementary Figure S1).

Definitions
Individual risks of stroke were assessed using the CHA2DS2-VASc score. The CHA2DS2-VASc score was calculated based on patients’ risk profile at recruitment. For patients from the Gulf SAFE registry, during which time the CHA2DS2-VASc score was in its initial period, this score was retrospectively calculated based on information from detailed patient records. Low-risk was defined as the CHA2DS2-VASc score of 0 in males and 1 in females, medium-risk as 1 in males and 2 in females, and high-risk as ≥2 in males or ≥3 in females. The CHADS2 (congestive HF, hypertension, age ≥75, DM, stroke/SE/TIA [doubled]) score of each patient was also calculated. ATT was defined as prescription of OAC (warfarin or non-vitamin K antagonist anticoagulant [NOAC]) or antiplatelets drugs (aspirin or clopidogrel). Major outcomes recorded included stroke events and all-cause mortality during one-year follow-up. Both ischemic stroke and transient ischemic attack (TIA) were identified as stroke events.
Statistical analysis

Descriptive analyses were used in this study. Following testing for normality, continuous variables in normal distribution were expressed as mean ± standard deviation (SD), or median ± interquartile range (IQR) for non-parametric distributions. Categorical variables were expressed as observed number of patients and percentages. Comparison between continuous variables were analysed using Student’s T test or Mann-Whitney U test, as appropriate. Difference between categorical variables were analysed using Pearson chi-square test.

Multivariable logistic regression analysis was used for testing independent risk factors for one-year outcome. The performance of the CHA$_2$DS$_2$-VASc score for predicting risk of stroke and mortality was analysed by area under curve (AUC). Bootstrap procedure with 1000 replicates was also used for validating the performance of the CHA$_2$DS$_2$-VASc score in the combined population, considering the differences among the two cohorts.

All tests were two-tailed. A p value <0.05 was considered as statistically significant. Analyses were performed using SPSS Statistics, version 23.0 (IBM, SPSS Inc) and STATA Software, version 14.0 (Stata Corp, College Station, TX).
Results

Baseline characteristics of the two populations are summarised in Table 1. Patients from Darlington were older and had higher prevalence of hypertension, previous stroke and TIA, with higher CHADS2 and CHA2DS2-VASc scores. Patients from Gulf SAFE countries had higher prevalence of DM, vascular disease and HF. The prescription rate of antiplatelet agents was higher in the patients from Gulf SAFE, as well as the rate of dual antithrombotic therapy, i.e., OAC plus antiplatelet drug. A higher percentage of AF patients from Darlington were categorised as high-risk (Supplementary Figure S2).

OAC prescription in Darlington and Gulf countries

ATT use increased with higher stroke risk strata in both populations, from 49.4% to 88.4% in Darlington and 85.1% to 93.7% in Gulf SAFE countries (Figure 1). OAC use also increased with higher stroke risk strata, from 23.5% to 46.8% in Darlington and 32.0% to 58.4% in Gulf countries. In both populations, OAC use in non-low risk categories of the both populations were less than 60%. In the high-risk categories, patients from Gulf SAFE countries had more use of dual antithrombotic therapy (28.8% vs. 5.2%). In the Gulf SAFE registry, for patients on anticoagulation (n=747), a total of 353 patients (47.3%) had at least three INR checks, and these had a mean TiTR of 63.5% (SD=37.0).

One-year risks of stroke and mortality

Patients from Gulf SAFE registry had higher rates of stroke for each risk category (Table 2). Stroke rates increased with higher risk strata in patients from Gulf SAFE countries. Mortality rates also increased with higher risk strata in both populations (Table 2). Among high-risk patients, one-year mortality rates were 11.4% and 16.8% in patients from Darlington and
Gulf SAFE countries, respectively. A relatively higher mortality risk was observed in each risk category in AF patients from Gulf SAFE registry compared with Darlington registry (Table 2). Among patients with high stroke risk, patients on OAC from the Gulf SAFE registry had high risk of stroke and mortality. Such difference was not shown in the non-OAC patients (see Supplementary Table S1).

Multivariable analysis for stroke and mortality events

On multivariable analysis, female sex, and previous stroke were independently associated with stroke events (see Table 3). Elderly age, female sex, HF and vascular disease were independent risk factors for mortality (see Table 3). Patients from Gulf SAFE countries had a doubled risk of stroke and a 67% higher risk of mortality compared with those from Darlington. OAC significantly reduced the risk of all-cause mortality by 45% in the whole study population.

In the multivariable analysis, OAC did not show a significant reduction of stroke events. We then performed a baseline comparison between patients with and without OAC. Patients with OAC had a significantly higher CHA$_2$DS$_2$-VASc score (3, IQR [2-5] vs. 3, IQR [1-4]; p=0.000) and higher percentage of patients with CHA$_2$DS$_2$-VASc score ≥2 (see Supplementary Table S2).

As demonstrated in the multivariable analysis, OAC was independently associated with mortality reduction; however, such reduction was only shown among patients from the Darlington registry (OAC vs. No-OAC: 6.2% vs. 12.4%, Darlington; 11.8% vs. 10.9% Gulf SAFE).
Predicting risks of stroke and mortality

The CHA$_2$DS$_2$-VASc score was a good predictor for the one-year risk of stroke in non-anticoagulated patients, with an AUC of 0.71 (95% confidence intervals [CI], 0.65-0.76) in the combined population (n=2036) (Supplementary Figure S3), also in UK and ME cohorts separately (AUC for Darlington [n=1179] of 0.74 [95% CI, 0.67-0.81]; AUC for Gulf [n=857] of 0.70 [95% CI, 0.63-0.77]). The CHA$_2$DS$_2$-VASc score also had good predictive ability for one-year mortality, with an AUC of 0.70 (95%CI, 0.68-0.72) in the combined population (Supplementary Figure S3), also in UK and ME cohorts separately (AUC for Darlington of 0.70 [95% CI, 0.67-0.73]; AUC for Gulf of 0.72 [95% CI, 0.68-0.76]).

The performances of the CHA$_2$DS$_2$-VASc score were confirmed by bootstrap procedure in the combined population, which gave an AUC of 0.64 (95%CI, 0.58-0.69) for stroke and of 0.62 (95%CI, 0.60-0.65) for mortality.
Discussion

In the present study, we have performed the first patient level comparisons of clinical characteristics, OAC use, and one-year risks of stroke and mortality amongst two cohorts of patients with AF. We show differences in stroke risk distribution, OAC use and one-year risks of stroke and mortality between patients with AF enrolled in the Darlington AF registry (UK) and the Gulf SAFE registry (ME).

Our principal findings are as follows: (i) While large percentages of patients with AF would be candidates for OAC in both populations, overall OAC use was suboptimal; (ii) High one-year rates of stroke and mortality were observed in both populations, especially in the high-risk patient category, but patients from Gulf SAFE registry had higher risk of stroke and mortality compared with those from Darlington registry; (iii) Female sex and previous stroke were independent factors associated with stroke, while elderly age, female sex, HF and vascular disease were independent risk factors for mortality; and (iv) The CHA\textsubscript{2}-DS\textsubscript{2}-VASc score showed good discrimination in predicting one-year risk of stroke in non-anticoagulated patients and mortality in the whole study population, as well as in the Darlington and Gulf SAFE cohorts separately.

As expected (and shown in the present study), the majority of patients with AF are candidates for OAC, given that the latter reduces stroke and mortality\textsuperscript{9}. In a prior study from Saudi Arabia, this percentage was as high as 92\%\textsuperscript{18}. Wide regional differences in OAC used among patients with AF have been reported. The EORP-AF registry (EURObservational Research Programme of AF) showed a high OAC use among European countries (84.9\%)\textsuperscript{19}. Also, the GLORIA-AF registry found highest OAC use in Europe (90.1\%), followed by Africa/ME
In the present study, there was still an unmet need given that OAC use was suboptimal, as is reflected by high one-year stroke and mortality risks.

Our study shows that even in anticoagulated patients, the one-year rate of stroke was still high, with 3.0% in Darlington and 5.3% in Gulf countries. This may suggest a suboptimal OAC management in these at-risk patients from both populations, given that OAC use was mainly vitamin K antagonists (VKA, e.g. warfarin). The effectiveness of the latter is highly dependent on the quality of anticoagulation control\textsuperscript{20}. In the Gulf SAFE registry, only 47.3% (n=353) patients had at least three INR checks across the 12 months of follow-up, and the TiTR was suboptimal (mean 63.5%). For the other patients without INR checks and corresponding dosage adjustment, the TiTR might be even lower. The suboptimal anticoagulation quality may translate to higher stroke and mortality rates in Gulf SAFE countries compared to Darlington, or to other differences not accounted for on multivariate analysis which did show an independent effect of study cohort (i.e., 2.18-fold higher risk in Gulf SAFE, vs. Darlington) on stroke. Unfortunately, we were unable to provide the TiTR information in the Darlington registry, which might have provided more details of anticoagulation quality in this population. We would speculate that these patients may have higher TiTR, considering a good anticoagulation quality control has consistently been shown in AF patients from the UK\textsuperscript{21, 22}.

In the multivariable analysis, OAC was associated with mortality reduction, which was only shown in the Darlington registry, but not in Gulf SAFE registry. A widely used active medical surveillance in the UK for anticoagulated patients might be the major reason, enabling routine good anticoagulation quality control and management of other
comorbidities. Indeed, in another study from UK, among patients with high stroke risk, OAC was associated with 11% to 73% reduced mortality\textsuperscript{23}.

For a reduced mortality among patients with AF, good OAC use may be not enough and management of other comorbidities is equally important. In the EORP-AF registry, one-year mortality was high (5.7%), with cardiovascular death being responsible for the majority (70%)\textsuperscript{24}. In a prospective, multicentre registry in China, the one-year all-cause mortality in patients with AF was 14.6\textsuperscript{25}. In the present study, mortality was high in both populations, especially among those with high CHA\textsubscript{2}DS\textsubscript{2}-VASc score. On multivariate analysis there was an independent effect of study cohort (i.e., 1.67-fold higher risk in Gulf SAFE, vs. Darlington) on mortality. Reasons for this may include a different health care level and relatively high prevalence of comorbidities (DM, HF and vascular disease) in Gulf SAFE at baseline.

Indeed, multiple risk factors were associated with the risks of stroke and mortality in patients with AF\textsuperscript{26}. Also, we confirm the good performance of the CHA\textsubscript{2}DS\textsubscript{2}-VASc score in predicting stroke and mortality as was demonstrated previously\textsuperscript{27-31}. Stroke only accounts for 10\% of the mortality seen in AF; whilst other cardiovascular diseases account for nearly 70\%\textsuperscript{32,33}. Hence, management of other coexisting cardiovascular diseases and risk factors is also necessary. To adequately identify at-risk patients may help implement more aggressive management strategies in a holistic and integrated manner to ensure a better outcome\textsuperscript{7}.

\textit{Limitations}

The present study is the first patient level comparisons of two cohorts of patients with AF, from the UK and ME. Nevertheless, there are some limitations. We did not consider patients’
preference which could affect the OAC decision\textsuperscript{34}. We did not have data on time in therapeutic range among patients on vitamin K anticoagulants in the Darlington cohort, and data on our two cohorts were collected before the wide use of non-VKA OACs (NOACs). Also, we could not report the risks of major bleeding and intracranial haemorrhage, which were not recorded. Darlington is one region in UK, while Gulf SAFE is from multiple countries and each may have differences in implementation and guideline adherence. The two registries were conducted among different healthcare providers, which could be another reason for the differences. This study was not able to differentiate which was the predominant factor, which needs further investigation. In addition, the two cohorts were collected in slightly different time periods. The Gulf SAFE study was conducted between 2010 to 2012, which was 2 to 3 years earlier than the Darlington registry. Over time, there might be some improvement, but considering that the Gulf SAFE study covers 23 centres from 6 Gulf countries, the improvement over 2-3 years may not be profound and thus, should not change the major conclusions of the present study.

Conclusion
Stroke prevention was generally suboptimal in two patient cohorts from UK and ME, which was associated with high one-year risks of stroke and mortality, particularly so amongst patients from ME. The higher risks for stroke and mortality in AF patients from ME countries (compared to a UK cohort) merits further studies to enable implementation of cardiovascular prevention strategies.
Declarations of interest

None directly related to this paper. GYHL: Consultant for Bayer/Janssen, BMS/Pfizer, Medtronic, Boehringer Ingelheim, Novartis, Verseon and Daiichi-Sankyo. Speaker for Bayer, BMS/Pfizer, Medtronic, Boehringer Ingelheim, and Daiichi-Sankyo. No fees are directly received personally.

Other authors: None declared.
References


FIGURE LEGENDS

Figure 1. Oral anticoagulant use in patients with atrial fibrillation in Darlington and Gulf SAFE countries (%) 

APT=antiplatelet therapy; ATT=antithrombotic therapy; OAC=oral anticoagulation
Table 1. Baseline characteristics and antithrombotic therapy in patients with AF from Darlington and Middle East

<table>
<thead>
<tr>
<th>Characteristics</th>
<th>All (n=3,998)</th>
<th>Darlington Registry (n=2,258)</th>
<th>Gulf SAFE Registry (n=1,740)</th>
<th>P value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Demographics</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Age, mean ± SD (y)</td>
<td>67.8 ± 16.6</td>
<td>75.6 ± 12.2</td>
<td>57.7 ± 16.0</td>
<td>&lt; 0.001</td>
</tr>
<tr>
<td>Female, No. (%)</td>
<td>1846 (46.2)</td>
<td>1040 (46.1)</td>
<td>806 (46.3)</td>
<td>0.868</td>
</tr>
<tr>
<td>Medical history, No. (%)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hypertension</td>
<td>2389 (59.8)</td>
<td>1404 (62.2)</td>
<td>985 (56.6)</td>
<td>&lt; 0.001</td>
</tr>
<tr>
<td>Diabetes mellitus</td>
<td>1041 (26.0)</td>
<td>489 (21.7)</td>
<td>552 (31.7)</td>
<td>&lt; 0.001</td>
</tr>
<tr>
<td>Vascular disease</td>
<td>945 (23.6)</td>
<td>388 (17.2)</td>
<td>557 (32.0)</td>
<td>&lt; 0.001</td>
</tr>
<tr>
<td>Previous stroke or TIA</td>
<td>631 (15.8)</td>
<td>428 (19.0)</td>
<td>203 (11.7)</td>
<td>&lt; 0.001</td>
</tr>
<tr>
<td>Heart failure</td>
<td>905 (22.6)</td>
<td>455 (20.2)</td>
<td>450 (25.9)</td>
<td>&lt; 0.001</td>
</tr>
<tr>
<td>Thrombotic risk</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CHADS₂ score, median (IQR)</td>
<td>2 (1-3)</td>
<td>2 (1-3)</td>
<td>1 (0-2)</td>
<td>&lt; 0.001</td>
</tr>
<tr>
<td>CHA₂DS₂-VASc score, median (IQR)</td>
<td>3 (2-4)</td>
<td>4 (2-5)</td>
<td>2 (1-4)</td>
<td>&lt; 0.001</td>
</tr>
<tr>
<td>Antithrombotic therapy, No. (%)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>OAC</td>
<td>1962 (49.1)</td>
<td>1079 (47.8)</td>
<td>883 (50.7)</td>
<td>0.063</td>
</tr>
<tr>
<td>APT</td>
<td>1962 (49.1)</td>
<td>921 (40.8)</td>
<td>1041 (59.8)</td>
<td>&lt; 0.001</td>
</tr>
<tr>
<td>OAC plus APT</td>
<td>449 (11.2)</td>
<td>110 (4.9)</td>
<td>339 (19.5)</td>
<td>&lt; 0.001</td>
</tr>
<tr>
<td>No ATT</td>
<td>423 (10.6)</td>
<td>368 (16.3)</td>
<td>155 (8.9)</td>
<td>&lt; 0.001</td>
</tr>
</tbody>
</table>
APT=antiplatelet therapy; ATT=antithrombotic therapy; CHADS₂ score=congestive heart failure, hypertension, age>75; diabetes mellitus, previous stroke or TIA [doubled]; CHA₂DS₂-VASc score=congestive heart failure, hypertension, age≥75 [doubled], diabetes mellitus, previous stroke or TIA [doubled], vascular disease, age 65-74, sex category [female]; IQR=inter quartile range; OAC=oral anticoagulant; SD=standard deviation; TIA=transient ischemic attack.
Table 2. One-year risks of stroke and mortality in Darlington and Gulf SAFE countries

<table>
<thead>
<tr>
<th>Characteristics</th>
<th>Stroke Risk* (95% CI)</th>
<th>Relative risk (95% CI)</th>
<th>P value</th>
<th>Mortality Risk* (95% CI)</th>
<th>Relative risk (95% CI)</th>
<th>P value</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Darlington</td>
<td>Gulf SAFE</td>
<td></td>
<td>Darlington</td>
<td>Gulf SAFE</td>
<td></td>
</tr>
<tr>
<td>Low risk</td>
<td>0.59 (0.00-1.75)</td>
<td>2.84 (1.25-4.44)</td>
<td>4.95</td>
<td>0.59 (0.00-1.75)</td>
<td>2.61 (1.08-4.13)</td>
<td>4.52(0.58-35.3)</td>
</tr>
<tr>
<td>Medium risk</td>
<td>0.00 (N/A)</td>
<td>5.25 (2.81-7.69)</td>
<td>N/A</td>
<td>0.42 (0.00-1.25)</td>
<td>5.86 (3.29-8.44)</td>
<td>14.7(1.95-110.6)</td>
</tr>
<tr>
<td>High risk</td>
<td>3.51 (2.67-4.35)</td>
<td>5.63 (4.20-7.07)</td>
<td>1.64</td>
<td>11.40 (9.95-12.9)</td>
<td>16.80 (14.5-19.1)</td>
<td>1.57(1.26-1.96)</td>
</tr>
</tbody>
</table>

*per 100 patient-years; CI=confidence interval; N/A=not applicable, because of no events in this patient group.
Table 3. Multivariable analysis of risk factors for stroke and death

<table>
<thead>
<tr>
<th>Characteristics</th>
<th>Stroke</th>
<th></th>
<th>Death</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>OR</td>
<td>95% CI</td>
<td>p value</td>
<td>OR</td>
</tr>
<tr>
<td>Elderly (≥ 75)</td>
<td>1.40</td>
<td>0.94-2.08</td>
<td>0.097</td>
<td>3.80</td>
</tr>
<tr>
<td>Female</td>
<td>1.51</td>
<td>1.08-2.12</td>
<td>0.017</td>
<td>1.31</td>
</tr>
<tr>
<td>Study cohort*</td>
<td>2.18</td>
<td>1.47-3.23</td>
<td>&lt; 0.001</td>
<td>1.67</td>
</tr>
<tr>
<td>Heart failure</td>
<td>1.27</td>
<td>0.87-1.86</td>
<td>0.213</td>
<td>2.78</td>
</tr>
<tr>
<td>Hypertension</td>
<td>0.91</td>
<td>0.63-1.32</td>
<td>0.622</td>
<td>0.90</td>
</tr>
<tr>
<td>Diabetes mellitus</td>
<td>1.14</td>
<td>0.78-1.65</td>
<td>0.505</td>
<td>1.150</td>
</tr>
<tr>
<td>Previous stroke</td>
<td>3.52</td>
<td>2.46-5.03</td>
<td>&lt; 0.001</td>
<td>1.21</td>
</tr>
<tr>
<td>Vascular disease</td>
<td>1.07</td>
<td>0.72-1.59</td>
<td>0.729</td>
<td>1.92</td>
</tr>
<tr>
<td>OAC use</td>
<td>1.01</td>
<td>0.72-1.40</td>
<td>0.974</td>
<td>0.55</td>
</tr>
</tbody>
</table>

* Darlington as reference; CI= confidence interval; OAC=oral anticoagulant; OR=odds ratio.
Figure 1
Highlights:

(i) Patients profiles regarding demographic factors, baseline comorbidities, and evaluated stroke risks were different between the two registries derived from different clinical settings;
(ii) While large percentages of patients with AF would be candidates for OAC in both populations, overall OAC use was suboptimal;
(iii) High one-year rates of stroke and mortality were observed in both populations, especially among patients from Gulf SAFE;
(iv) Female sex and previous stroke were independent factors associated with stroke; while elderly age, female sex, HF and vascular disease were independent risk factors for mortality.